Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Hematology
Disease Category: Acute Myelogenous Leukemia (AML)
Trial Information
SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717)
The study will determine the activity of SCH 727965 treatment in patients with acute myelogenous leukemia (AML) and patients with acute lymphoblastic leukemia (ALL). The study will also determine the activity of SCH 727965 treatment in patients with AML who experience disease progression after standard treatment with gemtuzumab ozogamicin.
Patient Inclusion Criteria:
- Age >=60 years, either sex, any race.
- Subject must be in first or second relapse, or have refractory disease, and not be considered a candidate for transplant
- Subject with ALL must be in first or second relapse, or have refractory disease, and not be considered a candidate for potentially curative therapy.
Patient Exclusion Criteria:
- Known central nervous system leukemia
- Previous hematopoietic stem cell transplantation
- For AML, previous treatment with gemtuzumab ozogamicin.
- Known active hepatitis B or C.
Cathy Spears, Research Manager
St. Francis Hospital and Health Centers
1500 N Albany Street, Suite 1001
Beech Grove, IN 46107
Phone: 317-782-7819
Fax: 317-782-7828
EMail: cathy.spears@ssfhs.org
View Google Map
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
